Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Zeltia SA’s Subsidiary, Noscira SA, To Propose Dissolution
Zeltia SA announced that its subsidiary, Noscira SA, has decided to hold the Extraordinary Shareholders’ Meeting on December 18, 2012 or December 19, 2012 and propose a dissolution of Noscira SA due to the deterioration of the company’s investment.
Latest Developments for Zeltia SA
- Zeltia SA's Subsidiary Noscira SA To Be Dissolved
- Zeltia SA’s Pharma Mar Receives 14 New Marketing Authorizations For Yondelis In 10 Countries-Reuters
- Zeltia SA Announces Negative Results From Phase II Trial Of Alzheimer Treatment-Reuters
- Zeltia SA Announces Results From Phase II Trial Of Noscira's Alzheimer's Treatment-Reuters
Latest Key Developments in Biotechnology
- Elite Pharmaceuticals Inc Announces Change In Executive Leadership
- iCo Therapeutics Inc Closes $3.4 Million Financing
- Cytrx Corp Announces Initial Results From Pharmacokinetics Clinical Trial With Aldoxorubicin In Solid Tumors
- Sanofi SA and Regeneron Pharmaceuticals Inc Announce Positive Phase 2a Results of Dupilumab in Asthma
- Share this
- Link this
- Digg this
Follow Reuters